Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine augmentation for negative symptoms in schizophrenia
IRCT20100520003979N9Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Atomoxetine augmentation with Placebo augmentation (2 arms). Primary endpoints: Lack of social interest, Frivolity and 4 more. Started Oct 2018; status: completed.
02
Drugs
atomoxetine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20100520003979N9.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100520003979N9.